Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 34

Sort by

Sort Order Select

Journal Articles

Novel Combinatorial Therapeutic Options in NEAT1-Depleted Multiple Myeloma Cells By the Integration of in Vitro and in silico Drug Screening Approaches

Noemi Puccio, Elisa Taiana, Gloria Manzotti, Elisabetta Mereu, Domenica Ronchetti, Cecilia Bandini, Ilaria Craparotta, Laura Di Rito, Marco Bolis, Veronica Manicardi, Valentina Fragliasso, Nicola Amodio, Niccolò Bolli, Stefano Luminari, Alessia Ciarrocchi, Roberto Piva, Antonino Neri

Blood (2023) 142 (Supplement 1): 6612.

https://doi.org/10.1182/blood-2023-190131

Published: 2023

Journal Articles

A MIR17HG-derived long noncoding RNA provides an essential chromatin scaffold for protein interaction and myeloma growth

Blood (2023) 141 (4): 391–405.

https://doi.org/10.1182/blood.2022016892

Published: 2023

Includes: Supplemental data

Journal Articles

Bioprocessing of MIR17HG Results in Long and Short Noncoding RNAs with Targetable Tumor-Promoting Activity in Multiple Myeloma

Blood (2022) 140 (Supplement 1): 1551–1552.

https://doi.org/10.1182/blood-2022-167604

Published: 2022

Journal Articles

Identifying Long Noncoding RNA Dependencies Using CRISPR Interference (CRISPRi)-Based Platform in Multiple Myeloma

Blood (2021) 138 (Supplement 1): 894.

https://doi.org/10.1182/blood-2021-151705

Published: 2021

Journal Articles

RNA Regulator of Lipogenesis (RROL) Is a Novel Lncrna Mediating Protein-Protein Interaction at Gene Regulatory Loci Driving Lipogenic Programs in Multiple Myeloma

Blood (2020) 136 (Supplement 1): 20–21.

https://doi.org/10.1182/blood-2020-142514

Published: 2020

Journal Articles

Targeting Myeloma Cell Metabolism Via Disruption of the Lnc-17-92 Transcriptional Program: Druggable New Vulnerability in Multiple Myeloma

Eugenio Morelli, MD, Mariateresa Fulciniti, PhD, Mehmet Kemal Samur, PhD, Caroline Ribeiro, PhD, Leon Wert-Lamas, PhD, Annamaria Gulla, MD, Anil Aktas Samur, PhD, Cinzia Federico, PhD, Francesca Scionti, PhD, Yao Yao, PhD, Nicola Amodio, PhD, Giada Bianchi, MD, Yu-Tzu Tai, PhD, Pierfrancesco Tassone, MD, Kenneth C. Anderson, MD, Carl D. Novina, MD PhD, Massimo Loda, MD, Nikhil C. Munshi, MD

Blood (2019) 134 (Supplement_1): 317.

https://doi.org/10.1182/blood-2019-130730

Published: 2019

Journal Articles

Activation of the Non-Canonical Estrogen Receptor Gper As a Novel Therapeutic Strategy Against WaldenstrÃ¶m Macroglobulinemia

Nicola Amodio, PhD, Giada Juli, PhD, Eugenio Morelli, MD, Maria Angelica Stamato, PhD, Maria Eugenia Gallo Cantafio, PhD, Cinzia Federico, PhD, Katia Todoerti, PhD, Emanuela Altomare, Katia Grillone, PhD, Marco Rossi, MD, Michele Cea, MD, Antonino Neri, MD, Mariateresa Fulciniti, PhD, Nikhil Munshi, MD, Pierosandro Tagliaferri, Pierfrancesco Tassone, MD

Blood (2018) 132 (Supplement 1): 1585.

https://doi.org/10.1182/blood-2018-99-110928

Published: 2018

Journal Articles

Inhibitor of DNA Binding 2 (ID2) Plays a Key Tumor Suppressor Role in Promoting Oncogenic Transformation in Multiple Myeloma

Tommaso Perini, MD, Raphael Szalat, MD, Mehmet Kemal Samur, PhD, Mariateresa Fulciniti, PhD, Michael A Lopez, Matthew Lawlor, Christopher J. Ott, PhD, Na Li, MD, Yan Xu, MD, Kenneth Wen, BS, Nicola Amodio, PhD, Eugenio Morelli, MD, Kenneth Anderson, MD, Fabio Ciceri, MD, Nikhil Munshi, MD

Blood (2018) 132 (Supplement 1): 60.

https://doi.org/10.1182/blood-2018-99-118401

Published: 2018

Journal Articles

Functional Role of Linc-RNAs in Multiple Myeloma: Linc-MIR17HG Affects Fatty Acid Biosynthesis Via transcriptional Regulation of ACC1 with Potential Therapeutic Implications

Eugenio Morelli, MD, Mariateresa Fulciniti, PhD, Mehmet Kemal Samur, PhD, Francesca Scionti, Annamaria Gulla, MD, Nicola Amodio, PhD, Giada Bianchi, MD, Tommaso Perini, MD, Cinzia Federico, PhD, Michael A Lopez, Maria Teresa Di Martino, Pierosandro Tagliaferri, Pierfrancesco Tassone, MD, Kenneth Anderson, MD, Nikhil Munshi, MD

Blood (2018) 132 (Supplement 1): 1925.

https://doi.org/10.1182/blood-2018-99-119572

Published: 2018

Journal Articles

Therapeutic vulnerability of multiple myeloma to MIR17PTi, a first-in-class inhibitor of pri-miR-17-92

Blood (2018) 132 (10): 1050–1063.

https://doi.org/10.1182/blood-2018-03-836601

Published: 2018

Includes: Supplemental data

Journal Articles

Th17 Cells Targeting By MiR-21 Inhibitor Impairs Multiple Myeloma Related Bone Disease

Marco Rossi, Emanuela Altomare, Nicola Amodio, PhD, Maria Teresa Di Martino, Marco Gaspari, Domenico Taverna, Domenica Scumaci, Francesco Conforti, Daniele Caracciolo, Cirino Botta, Cinzia Federico, Annamaria Gullà, Eugenio Morelli, Francesca Scionti, Mariamena Arbitrio, MD, Paola Critelli, Antonino Neri, Pierosandro Tagliaferri, Pierfrancesco Tassone, MD

Blood (2017) 130 (Supplement 1): 4380.

https://doi.org/10.1182/blood.V130.Suppl_1.4380.4380

Published: 2017

Journal Articles

LNA -Gapmer Antisense Oligonucleotides Targeting the Oncogenic Lncrna MALAT1 Trigger Anti-Multiple Myeloma Activity By Proteasome Blockade

Nicola Amodio, PhD, Maria Angelica Stamato, PhD, Giada Juli, PhD, Eugenio Morelli, Martina Manzoni, Elisa Taiana, Marco Rossi, Mariamena Arbitrio, MD, Mariateresa Fulciniti, PhD, Nikhil Munshi, MD, Antonino Neri, Pierosandro Tagliaferri, Pierfrancesco Tassone, MD

Blood (2017) 130 (Supplement 1): 1762.

https://doi.org/10.1182/blood.V130.Suppl_1.1762.1762

Published: 2017

Journal Articles

Functional role and therapeutic targeting of p21-activated kinase 4 in multiple myeloma

Blood (2017) 129 (16): 2233–2245.

https://doi.org/10.1182/blood-2016-06-724831

Published: 2017

Includes: Supplemental data

Journal Articles

Arginine Methylation Mediated By PRMT5 Has Significant Biological and Clinical Impact in Multiple Myeloma

Annamaria Gulla, MD, Teru Hideshima, MD PhD, Giada Bianchi, MD, Mariateresa Fulciniti, PhD, Mehmet K. Samur, PhD, Yu-Tzu Tai, PhD, Jun Qi, PhD, Takeshi Harada, MD PhD, Eugenio Morelli, MD, Nicola Amodio, PhD, Ruben D. Carrasco, MD PhD, Pierosandro Tagliaferri, MD, Nikhil C. Munshi, MD, Pierfrancesco Tassone, MD, Kenneth C. Anderson, MD

Blood (2016) 128 (22): 1140.

https://doi.org/10.1182/blood.V128.22.1140.1140

Published: 2016

Journal Articles

Pharmacokinetics and Biodistribution of Locked Nucleic Acid (LNA)-Mir-221 Inhibitor: A New Promising Anti-Myeloma Agent

Maria Eugenia Gallo Cantafio, PhD, Annamaria Gulla, MD, Nicola Amodio, PhD, Emanuela Leone, PhD, Eugenio Morelli, MD, Lavinia Biamonte, PhD, Antonino Neri, Pr, MD, Pierosandro Tagliaferri, MD, Pierfrancesco Tassone, MD, Maria Teresa Di Martino

Blood (2015) 126 (23): 3025.

https://doi.org/10.1182/blood.V126.23.3025.3025

Published: 2015

Journal Articles

Growth Inhibition and Synergistic Induction of Apoptosis By Synthetic Mir-125b-5p Mimics and Myc-Targeting Agents in Human Myeloma Cell Lines

Lavinia Biamonte, PhD, Cinzia Federico, PhD, Eugenio Morelli, MD, Emanuela Leone, PhD, Maria Eugenia Gallo Cantafio, PhD, Maria Teresa Di Martino, Nicola Amodio, PhD, Marco Rossi, MD, Antonino Neri, Pr, MD, Pierosandro Tagliaferri, MD, Pierfrancesco Tassone, MD

Blood (2015) 126 (23): 3019.

https://doi.org/10.1182/blood.V126.23.3019.3019

Published: 2015

Journal Articles

Selective Activation of the Non-Classical Estrogen Receptor Gper Elicits Potent Anti-Tumor Activity in Multiple Myeloma

Nicola Amodio, PhD, Enrica Romeo, Maria Angelica Stamato, Eugenio Morelli, MD, Mariateresa Fulciniti, PhD, Lavinia Raimondi, Marzia Leotta, Maria Teresa Di Martino, Pierosandro Tagliaferri, MD, Nikhil C. Munshi, MD, Pierfrancesco Tassone, MD

Blood (2015) 126 (23): 916.

https://doi.org/10.1182/blood.V126.23.916.916

Published: 2015

Journal Articles

Selective G-Protein Estrogen Receptor (GPER) Activation Triggers Anti-Multiple Myeloma Activity and Synergizes with MiR-29b-Inducing Drugs

Nicola Amodio, PhD, Marzia Leotta, MD, Eugenio Morelli, MD, Teresa Calimeri, MD PhD, Anna Maria Gullà, MD, Maria Angelica Stamato, Enrica Romeo, Umberto Foresta, PhDstudent, Antonino Neri, Maria Teresa Di Martino, PhD, Pierosandro Tagliaferri, MD, Pierfrancesco Tassone, MD

Blood (2014) 124 (21): 4725.

https://doi.org/10.1182/blood.V124.21.4725.4725

Published: 2014

Journal Articles

Targeting Aberrant Non-Homologous End Joining in Multiple Myeloma: Role of the Classical and Alternative Pathways in Genomic Instability

Teresa Calimeri, MD PhD, Daniele Caracciolo, MD, Nicola Amodio, PhD, Mehmet Kemal Samur, PhD, Marzia Leotta, MD, Mariateresa Fulciniti, PhD, Marco Rossi, MD, Stephane Minvielle, Herve Avet-Loiseau, Pierosandro Tagliaferri, MD, Masood Shammas, PhD, Kenneth C. Anderson, Pierfrancesco Tassone, MD, Nikhil C. Munshi, MD

Blood (2014) 124 (21): 3417.

https://doi.org/10.1182/blood.V124.21.3417.3417

Published: 2014

Journal Articles

Cytoskeleton Regulator PAK4 Plays a Role in Growth and Survival of Myeloma with a Potential Therapeutic Intervention Using PAK4 Allosteric Modulators (PAMs)

Mariateresa Fulciniti, PhD, Rajya Lakshmi Bandi, BS, Nicola Amodio, PhD, Antonia Cagnetta, MD, William Senapedis, PhD, Erkan Baloglu, PhD, Kenneth C. Anderson, MD, Nikhil C. Munshi, MD

Blood (2014) 124 (21): 3381.

https://doi.org/10.1182/blood.V124.21.3381.3381

Published: 2014

NARROW

Novel Combinatorial Therapeutic Options in NEAT1-Depleted Multiple Myeloma Cells By the Integration of in Vitro and in silico Drug Screening Approaches

A MIR17HG-derived long noncoding RNA provides an essential chromatin scaffold for protein interaction and myeloma growth

Bioprocessing of MIR17HG Results in Long and Short Noncoding RNAs with Targetable Tumor-Promoting Activity in Multiple Myeloma

Identifying Long Noncoding RNA Dependencies Using CRISPR Interference (CRISPRi)-Based Platform in Multiple Myeloma

RNA Regulator of Lipogenesis (RROL) Is a Novel Lncrna Mediating Protein-Protein Interaction at Gene Regulatory Loci Driving Lipogenic Programs in Multiple Myeloma

Targeting Myeloma Cell Metabolism Via Disruption of the Lnc-17-92 Transcriptional Program: Druggable New Vulnerability in Multiple Myeloma

Activation of the Non-Canonical Estrogen Receptor Gper As a Novel Therapeutic Strategy Against WaldenstrÃ¶m Macroglobulinemia

Inhibitor of DNA Binding 2 (ID2) Plays a Key Tumor Suppressor Role in Promoting Oncogenic Transformation in Multiple Myeloma

Functional Role of Linc-RNAs in Multiple Myeloma: Linc-MIR17HG Affects Fatty Acid Biosynthesis Via transcriptional Regulation of ACC1 with Potential Therapeutic Implications

Therapeutic vulnerability of multiple myeloma to MIR17PTi, a first-in-class inhibitor of pri-miR-17-92

Th17 Cells Targeting By MiR-21 Inhibitor Impairs Multiple Myeloma Related Bone Disease

LNA -Gapmer Antisense Oligonucleotides Targeting the Oncogenic Lncrna MALAT1 Trigger Anti-Multiple Myeloma Activity By Proteasome Blockade

Functional role and therapeutic targeting of p21-activated kinase 4 in multiple myeloma

Arginine Methylation Mediated By PRMT5 Has Significant Biological and Clinical Impact in Multiple Myeloma

Pharmacokinetics and Biodistribution of Locked Nucleic Acid (LNA)-Mir-221 Inhibitor: A New Promising Anti-Myeloma Agent

Growth Inhibition and Synergistic Induction of Apoptosis By Synthetic Mir-125b-5p Mimics and Myc-Targeting Agents in Human Myeloma Cell Lines

Selective Activation of the Non-Classical Estrogen Receptor Gper Elicits Potent Anti-Tumor Activity in Multiple Myeloma

Selective G-Protein Estrogen Receptor (GPER) Activation Triggers Anti-Multiple Myeloma Activity and Synergizes with MiR-29b-Inducing Drugs

Targeting Aberrant Non-Homologous End Joining in Multiple Myeloma: Role of the Classical and Alternative Pathways in Genomic Instability

Cytoskeleton Regulator PAK4 Plays a Role in Growth and Survival of Myeloma with a Potential Therapeutic Intervention Using PAK4 Allosteric Modulators (PAMs)

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only